Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.
Alterity Therapeutics presented data from their Phase 2 clinical trial of ATH434 at the American Neurological Association Annual Meeting, showing the drug’s efficacy in slowing disease progression in Multiple System Atrophy (MSA) and its favorable safety profile. The trial demonstrated significant improvements in disease severity and motor performance, reinforcing ATH434’s potential as a disease-modifying therapy and generating optimism in the medical community.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their lead candidate, ATH434, is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, with potential applications in treating Parkinson’s disease and Multiple System Atrophy (MSA).
YTD Price Performance: 20.0%
Average Trading Volume: 13,499,487
Technical Sentiment Signal: Sell
Current Market Cap: A$115.1M
See more data about ATH stock on TipRanks’ Stock Analysis page.